FDA approves first AI test to guide breast cancer chemotherapy decisions

According to estimates from 2022, about 2.3 million females around the world were newly diagnosed with breast cancer..The U.S. FDA recently cleared the ArteraAI Breast digital pathology-based risk stratification tool to help doctors predict the likelihood of metastasis in patients with early-stage HR+/HER2- breast cancer to help determine the intensity of their treatment.

Read more here.

Previous post
Back to list
Next post